MAYNE Pharma Group has signed a 20year exclusive supply and license agreement with Mithra Pharmaceuticals to commercialise a novel oral contraceptive (OC) comprising Estetrol and drospirenone, in the US.
Launch is planned for the first half of 2021, with Mayne anticipating peak annual sales of more than US$200m.
The above article was sent to subscribers in Pharmacy Daily's issue from 03 Oct 19
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 03 Oct 19
